| __timestamp | Evotec SE | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17990000 | 40786000 |
| Thursday, January 1, 2015 | 25166000 | 47876000 |
| Friday, January 1, 2016 | 27013000 | 52035000 |
| Sunday, January 1, 2017 | 42383000 | 55348000 |
| Monday, January 1, 2018 | 57012000 | 65276000 |
| Tuesday, January 1, 2019 | 66546000 | 82720000 |
| Wednesday, January 1, 2020 | 77238000 | 89118000 |
| Friday, January 1, 2021 | 105445000 | 181193000 |
| Saturday, January 1, 2022 | 156190000 | 174078000 |
| Sunday, January 1, 2023 | 169610000 | 184232000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, understanding operational efficiency is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Veracyte, Inc. and Evotec SE from 2014 to 2023. Over this period, Veracyte's SG&A expenses grew by approximately 352%, while Evotec's increased by about 843%. Notably, in 2023, Veracyte's expenses were 9% higher than Evotec's, highlighting a significant shift from 2014 when Veracyte's expenses were more than double those of Evotec. This trend suggests Evotec's aggressive expansion strategy, while Veracyte maintains a steady growth trajectory. Investors and industry analysts should consider these trends when evaluating the companies' operational strategies and market positioning. The data underscores the importance of balancing growth with cost efficiency in the biotech sector.
Vertex Pharmaceuticals Incorporated vs Evotec SE: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Veracyte, Inc.
Selling, General, and Administrative Costs: argenx SE vs Evotec SE
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Evotec SE
Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Evotec SE
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Evotec SE
Sarepta Therapeutics, Inc. vs Veracyte, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Alkermes plc vs Evotec SE Trends and Insights
SG&A Efficiency Analysis: Comparing TG Therapeutics, Inc. and Veracyte, Inc.
Amneal Pharmaceuticals, Inc. or Veracyte, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Evotec SE
SG&A Efficiency Analysis: Comparing Veracyte, Inc. and ACADIA Pharmaceuticals Inc.